PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database
- PMID: 17868976
- DOI: 10.1016/j.eururo.2007.08.047
PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database
Abstract
Objectives: As a result of prostate-specific antigen (PSA) screening, most men today with prostate cancer present with localized disease and serum PSA values < 10 ng/ml. Within this context, it is debated whether PSA remains an important prognostic variable in more recently treated patients. We examined the prognostic significance of preoperative PSA to predict pathologic stage and biochemical progression among men undergoing radical prostatectomy in the new millennium (2000-2006).
Methods: We performed a review of 925 men with prostate cancer treated by radical prostatectomy since 2000 within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. We examined the association between preoperative PSA and risk of adverse pathologic features and biochemical progression using logistic regression and Cox proportional hazards analysis.
Results: After adjusting for multiple clinical preoperative characteristics, higher preoperative PSA values were associated with increased odds of extracapsular extension (p<0.001), positive surgical margins (p<0.001), and seminal vesicle invasion (p<0.001) and increased risk of biochemical progression (p=0.009). When the analyses were limited to the 690 men with a preoperative PSA<10 ng/ml and after adjusting for multiple clinical characteristics, higher preoperative PSA values remained associated with increased risk of biochemical progression (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.06-1.28, p=0.002). Even among the 448 men with a PSA<10 ng/ml and clinical stage T1c disease, preoperative PSA was associated with increased risk of biochemical progression (HR 1.14, 95%CI 1.00-1.31, p=0.047).
Conclusions: PSA remains an important prognostic marker among men diagnosed with prostate cancer in the new millennium treated with radical prostatectomy and remains an important predictor of outcome even among men with preoperative PSA level < 10 ng/ml.
Similar articles
-
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7. BJU Int. 2008. PMID: 18691175
-
Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.Cancer. 2006 Sep 15;107(6):1265-72. doi: 10.1002/cncr.22116. Cancer. 2006. PMID: 16900523
-
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.J Urol. 2006 Aug;176(2):554-8. doi: 10.1016/j.juro.2006.03.058. J Urol. 2006. PMID: 16813888
-
Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis.Urology. 1998 Jun;51(6):884-9; discussion 889-90. Urology. 1998. PMID: 9609622 Review.
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.J Urol. 2007 Feb;177(2):540-5. doi: 10.1016/j.juro.2006.10.097. J Urol. 2007. PMID: 17222629 Review.
Cited by
-
[Rational imaging of metastasized tumor diseases].Internist (Berl). 2013 Jul;54(7):803-9. doi: 10.1007/s00108-012-3241-0. Internist (Berl). 2013. PMID: 23736960 Review. German.
-
Dendritic cell-based immunotherapy for prostate cancer.Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4. Clin Dev Immunol. 2010. PMID: 21076523 Free PMC article. Review.
-
Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia.Prostate Int. 2013;1(1):16-22. doi: 10.12954/PI.12012. Epub 2013 Feb 4. Prostate Int. 2013. PMID: 24223397 Free PMC article.
-
A population-based propensity score matching analysis of risk factors and the impact on survival associated with refusal of cancer-directed surgery in patients with prostate cancer.Sci Rep. 2024 Apr 25;14(1):9494. doi: 10.1038/s41598-024-60180-w. Sci Rep. 2024. PMID: 38664545 Free PMC article.
-
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Vaccine. 2011 Sep 2;29(38):6485-97. doi: 10.1016/j.vaccine.2011.06.088. Epub 2011 Jul 7. Vaccine. 2011. PMID: 21741424 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous